These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36884148)

  • 1. A phase I dose-escalation study of SYHA1813, a VEGFR and CSF1R inhibitor, in patients with recurrent High-Grade Gliomas or Advanced Solid Tumors.
    Kang Z; Li S; Lin Y; Li Y; Mao Y; Zhang J; Lei T; Wang H; Su Y; Yang Y; Qiu J; Li W
    Invest New Drugs; 2023 Apr; 41(2):296-305. PubMed ID: 36884148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies.
    Li J; Zhao X; Chen L; Guo H; Lv F; Jia K; Yv K; Wang F; Li C; Qian J; Zheng C; Zuo Y
    BMC Cancer; 2010 Oct; 10():529. PubMed ID: 20923544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
    Shapiro GI; McCallum S; Adams LM; Sherman L; Weller S; Swann S; Keer H; Miles D; Müller T; Lorusso P
    Invest New Drugs; 2013 Jun; 31(3):742-50. PubMed ID: 23054208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.
    Dasari A; Hamilton EP; Falchook GS; Wang JS; Li D; Sung MW; Chien C; Nanda S; Tucci C; Hahka-Kemppinen M; Paulson AS
    Invest New Drugs; 2023 Jun; 41(3):421-430. PubMed ID: 37074571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
    Pedersen KS; Grierson PM; Picus J; Lockhart AC; Roth BJ; Liu J; Morton A; Chan E; Huffman J; Liang C; Wang-Gillam A; Tan B
    Invest New Drugs; 2021 Oct; 39(5):1298-1305. PubMed ID: 33738668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors.
    Drevs J; Siegert P; Medinger M; Mross K; Strecker R; Zirrgiebel U; Harder J; Blum H; Robertson J; Jürgensmeier JM; Puchalski TA; Young H; Saunders O; Unger C
    J Clin Oncol; 2007 Jul; 25(21):3045-54. PubMed ID: 17634482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
    Lopez J; Lai-Kwon J; Molife R; Welsh L; Tunariu N; Roda D; Fernández-García P; Lladó V; McNicholl AG; Rosselló CA; Taylor RJ; Azaro A; Rodón J; Sludden J; Veal GJ; Plummer R; Urruticoechea A; Lahuerta A; Mujika K; Escribá PV
    Br J Cancer; 2023 Sep; 129(5):811-818. PubMed ID: 37488446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.
    Soria JC; DeBraud F; Bahleda R; Adamo B; Andre F; Dientsmann R; Delmonte A; Cereda R; Isaacson J; Litten J; Allen A; Dubois F; Saba C; Robert R; D'Incalci M; Zucchetti M; Camboni MG; Tabernero J
    Ann Oncol; 2014 Nov; 25(11):2244-2251. PubMed ID: 25193991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
    Manley PE; Trippett T; Smith AA; Macy ME; Leary SES; Boklan J; Cohen KJ; Goldman S; Kilburn LB; Dhall G; Devin J; Herzog CE; Partap S; Fauchet F; Badreddine E; Bernard JP; Chi SN
    Pediatr Blood Cancer; 2018 Sep; 65(9):e27217. PubMed ID: 29750396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against glioblastoma.
    Liu Y; Zhan Z; Kang Z; Li M; Lv Y; Li S; Tong L; Feng F; Li Y; Zhang M; Xue Y; Chen Y; Zhang T; Song P; Su Y; Shen Y; Sun Y; Yang X; Chen Y; Yao S; Yang H; Wang C; Geng M; Li W; Duan W; Xie H; Ding J
    Acta Pharm Sin B; 2023 Dec; 13(12):4748-4764. PubMed ID: 38045044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
    Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
    Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors.
    Cao J; Zhang J; Peng W; Chen Z; Fan S; Su W; Li K; Li J
    Cancer Chemother Pharmacol; 2016 Aug; 78(2):259-69. PubMed ID: 27299749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.
    Bahleda R; Meric-Bernstam F; Goyal L; Tran B; He Y; Yamamiya I; Benhadji KA; Matos I; Arkenau HT
    Ann Oncol; 2020 Oct; 31(10):1405-1412. PubMed ID: 32622884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.
    Fields EC; Damek D; Gaspar LE; Liu AK; Kavanagh BD; Waziri A; Lillehei K; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):51-7. PubMed ID: 21035955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
    Yamamoto N; Tamura T; Yamamoto N; Yamada K; Yamada Y; Nokihara H; Fujiwara Y; Takahashi T; Murakami H; Boku N; Yamazaki K; Puchalski TA; Shin E
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1165-72. PubMed ID: 19308410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
    Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
    Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.